Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Treasury Shares (2020 - 2025)

Adma Biologics (ADMA) has disclosed Treasury Shares for 1 consecutive years, with $32.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed N/A year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2025, changed N/A, and an annual FY2025 reading of $1.9 million, down 66.6% over the prior year.
  • Treasury Shares was $1.9 million for Q4 2025 at Adma Biologics, up from $512000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $5.9 million in Q1 2025 and bottomed at $512000.0 in Q3 2025.
  • Average Treasury Shares over 5 years is $3.7 million, with a median of $4.6 million recorded in 2021.
  • Peak annual rise in Treasury Shares hit 591.18% in 2022, while the deepest fall reached 36.08% in 2022.
  • Year by year, Treasury Shares stood at $4.5 million in 2021, then plummeted by 36.08% to $2.9 million in 2022, then surged by 62.45% to $4.7 million in 2023, then grew by 5.42% to $4.9 million in 2024, then tumbled by 60.91% to $1.9 million in 2025.
  • Business Quant data shows Treasury Shares for ADMA at $32.1 million in Q4 2025, $23.2 million in Q3 2025, and $15.1 million in Q2 2025.